Avalon BioVentures I

Avalon BioVentures I is a venture capital firm based in La Jolla, California, specializing in biotechnology investments. The firm focuses on companies developing innovative therapies and technologies, aiming to accelerate the development and delivery of effective treatments in oncology, autoimmune diseases, and rare enzyme disorders. By integrating robust R&D, clinical, regulatory, and manufacturing capabilities, Avalon BioVentures I supports the transition of novel therapies from gene to market with speed, precision, and scalability.

The firm's investment strategy encompasses various stages, including Seed, Early Stage, Series A, Series B, Growth, Late Stage, and Pre-IPO, with a geographical focus on the United States. Avalon BioVentures I has invested in companies such as Arialys Therapeutics and Valora Therapeutics, contributing to advancements in the biotechnology sector. The firm's leadership combines deep scientific expertise with strategic execution across R&D, regulatory, capital markets, and global operations, collectively advancing over 20 pipeline assets and executing IPOs on both NYSE and Nasdaq, raising over $500 million through equity and debt offerings.

Avalon BioVentures I's commitment to innovation and partnership in life sciences drives its mission to bring transformative therapies to patients worldwide. By leveraging its extensive network of investors and industry partners, the firm supports innovators throughout the entire journey, from academic research and funding to building the necessary commercialization framework for final products, helping them achieve market success.